December 21, 2018
Authored and Edited by Katherine T. Leonard; Shana K. Cyr, Ph.D.
On December 12, 2018, FDA issued a proposed rule to amend the definition of “biological product” to conform to the definition provided by BPCIA. The proposed rule would also provide FDA’s interpretation of the statutory terms “protein” and “chemically unsynthesized polypeptide.” If finalized, the rule would take effect on the earlier of 60 days after publication in the Federal Register or March 23, 2020.
The proposed rule defines “biological product” as “a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein (except any chemically synthesized polypeptide), or analogous product, or arsphenamine or derivative of arsphenamine (or any other trivalent organic arsenic compound), applicable to the prevention, treatment, or cure of a disease or condition of human beings.” This is consistent with BPCIA’s definition that includes proteins in the definition of biological products.
Additionally, the proposed rule adds a definition for “protein” as “any alpha amino acid polymer with a specific, defined sequence that is greater than 40 amino acids in size.” It also adds a definition for “chemically synthesized polypeptide” as “any amino acid polymer that is made entirely by chemical synthesis and is greater than 40 amino acids but less than 100 amino acids in size.” The proposed rule indicates that for purposes of these two definitions, “[w]hen two or more amino acid chains in an amino acid polymer are associated with each other in a manner that occurs in nature, the size of the amino acid polymer…will be based on the total number of amino acids in those chains, and will not be limited to the number of amino acids in a contiguous sequence.”
Readers are encouraged to read the proposed rule, also available on Federal Register's website.
FDA Guidance, Food and Drug Administration (FDA), abbreviated biologic license application (aBLA), Biologic License Application (BLA), Biologics Price Competition and Innovation Act (BPCIA)
Copyright © 2018 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
INCONTESTABLE® Blog
April 19, 2024
Conference
2nd Annual Forum on IP, Funding and Tech Strategies for Novel Therapeutic Modalities
March 20, 2024
Boston
Webinar
February 15, 2024
Webinar
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.